Neumora Therapeutics Files 2025 Proxy Statement
Ticker: NMRA · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
Related Tickers: NMRA
TL;DR
Neumora (NMRA) filed its proxy statement. Get ready for shareholder votes.
AI Summary
Neumora Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for the fiscal year ending December 31, 2024. The company, formerly known as RBNC Therapeutics, Inc. until September 29, 2021, is based in Watertown, MA. This filing is related to the solicitation of proxies for their upcoming shareholder meeting.
Why It Matters
This filing provides shareholders with crucial information regarding the company's governance, executive compensation, and proposals to be voted on at the upcoming annual meeting, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- RBNC Therapeutics, Inc. (company) — Former company name
- 20250429 (date) — Filing date
- 2024-12-31 (date) — Fiscal year end
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company to solicit proxies from its shareholders for an upcoming shareholder meeting.
When was Neumora Therapeutics, Inc. formerly known as RBNC Therapeutics, Inc.?
Neumora Therapeutics, Inc. was formerly known as RBNC Therapeutics, Inc. until September 29, 2021.
What is Neumora Therapeutics, Inc.'s business address?
Neumora Therapeutics, Inc.'s business address is 490 Arsenal Way, Suite 200, Watertown, MA 02472.
What is the SIC code for Neumora Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Neumora Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
On what date was this DEF 14A filed?
This DEF 14A filing was made on April 29, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Neumora Therapeutics, Inc. (NMRA).